Start the conversation
Aimmune Therapeutics Inc. (Nasdaq: AIMT) has been all over the place since shares of the Brisbane, Calif.-based food-allergy biotech soared 50% in its initial public offering (IPO) back in early August.
We anticipated the whipsawing, which is why we urged folks to use an "accumulate" strategy - and a time frame of two years or more.
Our view hasn't changed.
And now we have company.
This is premium content for Private Briefing subscribers only.